Related Experiment Video
Updated: Jun 1, 2025
Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
Published on: July 5, 2018
Optimizing antibody stability and efficacy in CD47- SIRPα inhibition via computational approaches
Kapil Laddha1, M Elizabeth Sobhia2
1Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, S.A.S Nagar, Mohali, Punjab, 160062, India.
Abstract:
CD47, a cell surface protein, serves as a "don't eat me" signal that prevents immune cells from engulfing healthy cells upon its interaction with SIRPα. Cancer cells exploit this mechanism by overexpressing CD47 to evade immune destruction. Blocking the interaction between CD47 and its receptor, SIRPα, is a promising therapeutic strategy. Targeting the interactions between these surface proteins with small molecules is quite challenging, and on the other hand, antibodies offer potential. However, the interactions between antigen (CD47) and antibody (B6H12.2) play a crucial role in this scenario, and increasing the affinity by mutating the interacting residues might impact the inclination and effectiveness of the antibody towards antigen. Thus, this study focuses on designing antibodies with increased affinity and stability towards the antigen compared to the wild-type. Residual scanning calculations were performed to mutate the interacting as well as the hydrophobic residues of the antibody and affinity was assessed. Computational approaches, including antigen-antibody docking studies and molecular dynamics simulations, were employed to evaluate the affinity, stability and therapeutic potential of these modified antibodies.
Insights
Researchers engineered enhanced antibodies targeting CD47, a protein overexpressed by cancer cells to evade immune responses. Computational methods improved antibody affinity and stability for potential cancer therapies.
Area of Science:
- Immunology
- Biotechnology
- Computational Biology
Background:
- CD47 is a cell surface protein acting as a "don't eat me" signal, preventing immune cells from attacking healthy cells via SIRPα interaction.
- Cancer cells hijack the CD47-SIRPα pathway by overexpressing CD47 to evade immune surveillance and destruction.
- Blocking the CD47-SIRPα interaction is a promising cancer immunotherapy strategy, with antibodies showing therapeutic potential.
Purpose of the Study:
- To design and computationally evaluate novel antibodies with increased affinity and stability against the CD47 antigen compared to wild-type antibodies.
- To investigate the impact of specific residue mutations on antibody-antigen interactions and overall therapeutic efficacy.
- To explore computational approaches for optimizing antibody-based cancer therapies.
Main Methods:
- Utilized residual scanning calculations to identify and mutate key interacting and hydrophobic residues in the B6H12.2 antibody.
- Performed antigen-antibody docking studies to predict binding modes and affinities of modified antibodies.
- Conducted molecular dynamics simulations to assess the stability and dynamic behavior of wild-type and engineered antibodies.
Main Results:
- Identified specific mutations that enhance the binding affinity and stability of the antibody towards CD47.
- Computational analyses demonstrated the potential therapeutic advantages of the designed antibodies over the wild-type.
- Validated the use of computational tools for rational antibody design and optimization.
Conclusions:
- Engineered antibodies targeting CD47 show improved affinity and stability, suggesting enhanced therapeutic potential in cancer treatment.
- Computational modeling is a valuable tool for optimizing antibody-antigen interactions and guiding the development of novel immunotherapies.
- This study provides a foundation for developing next-generation CD47-blocking antibodies for cancer immunotherapy.
